key: cord-1003921-gbvpvqzi
authors: Sarkar, Rakesh; Saha, Ritubrita; Mallick, Pratik; Sharma, Ranjana; Kaur, Amandeep; Dutta, Shanta; Chawla-Sarkar, Mamta
title: Emergence of a Novel SARS-CoV-2 Pango Lineage B.1.1.526 in West Bengal, India
date: 2021-12-04
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.11.020
sha: 7bfc35add6bd585e4bb1c69d8848f4693a54baf7
doc_id: 1003921
cord_uid: gbvpvqzi

BACKGROUND: Since its inception in late 2019, SARS-CoV-2 has been evolving continuously by procuring mutations, leading to emergence of numerous variants, causing second wave of pandemic in many countries including India in 2021. To control this pandemic continuous mutational surveillance and genomic epidemiology of circulating strains is very important to unveil the emergence of the novel variant and also monitor the evolution of existing variants. METHODS: SARS-CoV-2 sequences were retrieved from GISAID database. Sequence alignment was performed with MAFT version 7. Phylogenetic tree was constructed by MEGA version 7 and UShER. RESULTS: In this study, we reported the emergence of a novel variant of SARS-CoV-2 named B.1.1.526 in India. This novel variant encompasses 129 SARS-CoV-2 strains which are characterized by the presence of 11 coexisting mutations including D614G, P681H and V1230L in S-glycoprotein. Out of these 129 sequences, 27 sequences also harbored E484K mutation in the S glycoprotein. Phylogenetic analysis revealed strains of this novel variant emerged from GR clade and formed a new cluster. Geographical distribution showed, out of 129 sequences, 126 were found in seven different states of India. Rest 3 sequences were observed in USA. Temporal analysis revealed this novel variant was first collected from Kolkata district of West Bengal, India. CONCLUSIONS: The D614G, P618H and E484K mutations have previously reported to favor increased transmissibility, enhanced infectivity and immune invasion, respectively. The transmembrane domain (TM) of S2 subunit anchors S glycoprotein to the virus envelope. The V1230L mutation present within the TM domain of S glycoprotein might strengthen the interaction of S protein with the viral envelope and increase S protein deposition to the virion, resulting in more infectious virion. Therefore, the new variant having D614 G, P618H, V1230L and E484K may have higher infectivity, transmissibility and immune invasion characteristics and thus need to be monitored closely.

Since the emergence of SARS-CoV-2, which is the cause of COVID-19, in December 2019, the virus has continuously been evolving by acquiring mutations throughout the genome with the progression of the pandemic [1] . Continuous efforts are being made towards SARS-CoV-2 genome sequencing and genomic epidemiology to investigate the virus evolution, their pathogenic potential and transmission. Gradual accumulation of mutation within the genome resulted in the delineation of circulating SARS-CoV-2 strains into different clades (L, S, O, V, G, GH, GR, GV, and GRY according to GISAID nomenclature), lineages and sublineages [2] . Special attention is given to the mutations which have evolved within the S glycoprotein due to their role in host cell receptor binding and entry, immune invasion and antibody neutralization [3] . Not surprisingly, most of the new mutations have been observed within the S glycoprotein, which could provide fitness advantage in terms of enhanced infectivity, transmissibility, immune invasion or antibody neutralization [4] .

The D614G, the first mutation emerged within the S glycoprotein, has been shown to be responsible for better infectivity and transmissibility of the virus A701V in Beta variant; L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y,  H655Y, T1027I in Gamma variant; and T19R, E156G, ∆157-158, L452R, T478K, In the current scenario, tracking new mutations within these newly emerged variants as well as investigating the emergence of new variants is crucial to take necessary preventive measures for effective public health responses. With the aim of tracing new mutations within the circulating SAR-CoV-2 strains in India during August 2020 to October 2021, we have identified the emergence of a novel SARS-CoV-2 lineage named B.1.1.526.This new variant is characterized by the presence of 12 co-existing mutations including E484K, D614G, P681H and V1230L in S glycoprotein.

High coverage full genome sequences of SARS-CoV-2 strains (n=8592), collected during August 2020 to October 2021 from India, were retrieved from Global Initiative on Sharing All Influenza Data (GISAID) on 9 th November 2021 [17] . The genome sequences of the prototype SARS-CoV-2 strain hCoV-19/Wuhan/WIV04/2019 (GISAID accession no. EPI_ISL_402124) and several clades/variants were also downloaded from GISAID database for the purpose of mutational analysis and construction of the phylogenetic tree.

We have performed non-synonymous mutational analysis of 25 proteins (NSP1-NSP16, S glycoprotein, NS3, E, M, NS6, NS7a, NS7b, NS8 and N) encoded by each of the 8592 SARS-CoV-2 strains collected during August 2020 to October 2021 from India. For performing mutational analysis of a specific protein, coding regions of that protein of 8592 SARS-CoV-2 genomes as well as prototype genome (hCoV-19/Wuhan/WIV04/2019) were translated to amino acid sequences by using TRANSEQ nucleotide-to-protein sequence conversion tool (EMBL-EBI, Cambridgeshire, UK). Next, the protein sequences (specific for a single protein) of 8592 SARS-CoV-2 strains and the prototype strain were aligned by using MEGA software (Version X) and observed for amino acid substitutions in the circulating SARS-CoV-2 strains with compared to the prototype strain [18] . The amino acid substitution observed at a particular location of the circulating strain was marked with the number according to its position with compared to first amino acid (which was considered as 1) of protein. . We accessed to the UCSC SARS-CoV-2 Genome Browser (https://genome.ucsc.edu/cgi-bin/hgPhyloPlace) and uploaded the sequence IDs of 129 sequences (Table S1 ) for the construction of the phylogenetic tree. UShER is a program that rapidly places new samples onto an existing phylogeny using maximum parsimony. It is particularly helpful in understanding the relationships of newly sequenced SARS-CoV-2 genomes with each other and with previously sequenced genomes in a global phylogeny.

By performing the whole genome mutational analysis of 8592 SARS-CoV-2 strains collected during August 2020 to October 2021 from India, we identified 126 SARS-CoV-2 strains having new set of 11 coexisting mutations among 7 different genes: D279N and L353F in NSP4; V26F in NSP8; P323L in NSP12; D614G, P681H and V1230L in S glycoprotein; G172C in NS3; V62L in NS8; and R203K and G204R in N gene. Table 1 is representing the 11 coexisting mutations associated with the seven different genes. We also searched for SARS-CoV-2 strains having this new set of coexisting mutation in other part of the world. Outside India, only 3 SARS-CoV-2 strains of this new variant were found in USA. Therefore, in total, 129 SARS-CoV-2 strains with 11 coexisting mutations were J o u r n a l P r e -p r o o f recognized. Interestingly, among 129 sequences, 27 sequences also harboured E484K mutation along with D614G, P681H and V1230L in the S glycoprotein. Table S1 is representing the names of 129 SARS-CoV-2 strains along with all the amino acid substitutions present within their genomes, including the 11 coexisting mutations.

In addition to 12 coexisting mutations including E484K, 186 different mutations were found throughout the genome of these 129 SARS-CoV-2 sequences. Among these 186 mutations, 36 were found in NSP3, 29 were found in S glycoprotein, 20 were found in NSP2, 17 were found in NS3, 10 were found in N, 9 were found in both NSP6 and NS8, 7 were found in both NSP14 and NSP16, 6 were found in both NSP5 and NSP15, 4 were found in each of NSP4, NSP9, NSP12 and NS7a, 3 were found in both NSP13 and E, 2 were found in each of NSP8, M and NS6, and single mutation was found in each of NSP1 and NSP7. No mutation was observed in NSP10, NSP11 and NS7b ( Table 2, Table S1 ). Among 186 different mutations, Q18stop mutation in NS8 protein was found to occur with highest frequency ( Table 2) . (Fig. 4A) . Temporal analysis revealed that the strain of lineage B.1.1.526 was first collected from Kolkata in West Bengal, India on 31 st August, 2020, following which it has spread to various districts of West Bengal during October, 2020 to January, 2021. The first strain of this new variant was isolated from Maharashtra, Delhi and Mizoram on December 2020 and from Gujarat, Haryana, and Rajasthan in early 2021 ( Fig. 4B and 4C ). The first incidence of B.1.1.526 was found in USA on 25 th January, 2021 in New Jersey (Fig. 4D ) Due to lack of metadata in GISAID, it was difficult to predict the association of three USA cases to India.

Emergence of new mutations in the S glycoprotein, which is involved in the binding of SARS-CoV-2 to the host cell receptor angiotensin-converting enzyme 2 (ACE2) and entry into the host cell, could have influence on virus binding, entry, immune invasion and antibody neutralization. Since the first emergence in December 2019, SARS-CoV-2 has acquired numerous mutations in the S glycoprotein that gave special adaptive advantages to the virus and play key role in the virus evolution so far. D614G, the first mutation appeared in the S glycoprotein, was detected in Germany in January 2020 and became the dominant mutation in all the circulating strains worldwide by June, 2020 [5] . Now it is present in all the circulating strains including all the VOC, VOI and VUM [4, 22] . Patients infected with D614G mutant had higher nasopharyngeal viral RNA loads, indicating its role in increased infectivity [5] . Wet lab experiments confirmed that the D614G variant enhances virus replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of the virions. Hamster infected with D614G variant produces higher infectious titers in nasal washes and the trachea, supporting the role of the G614G mutation in high transmissibility. It has also been demonstrated that D614G mutation confers higher susceptibility to serum neutralization [23] . Another study showed that pseudovirus particles carrying S-G614 enter ACE2 overexpressing cells more efficiently than those with S-D614. This increased entry correlates with less S1 domain shedding and higher S protein incorporation into the virion. However, S614 does not alter S protein binding to ACE2 or neutralization sensitivity to pseudoviruses [24]. K417N and K417T mutations, detected in the receptor binding domain (RBD) of S glycoprotein of Beta and Gamma variant respectively, have been shown to have potential role in immune escape [25, 26] . In addition to immune evasion, both K417N and K417T are expected to moderately decrease ACE2binding affinity of S glycoprotein [27] . Another RBD mutation L452R, appeared in Delta variant, made the conformation of the S protein more stable, leading to the increased affinity of the virus to ACE2 receptor. L452 residue did not directly interact with ACE2, but could affect the structural stability of the region by which S protein interacts with ACE2 and facilitate SARS-CoV-2 entry into the host cell [28] . In addition, L452R mutation induces the conformational change of RBD and reduces the ability of monoclonal antibodies and convalescent sera to neutralize the virus [29]. N501Y mutation, shared by the three VOCs Alpha, Beta and Gamma, could enhance the affinity of the S protein with ACE2, especially with the side chains of residues Y41 and K353 of ACE2 [30-32]. In addition, N501Y mutation enabled the virus to infect BALB/c mice, which expanded its host range. Mutation at E484 site of RBD domain exists in the form of K484 in Beta and Gamma variants while Q484 in Kappa variant. E484 site may be one of the important immune dominant epitopes of S glycoprotein because mutation of this site to K, Q, or P, decreases the neutralization ability of convalescent serum and some antibodies [33-38].

The present study primarily focused on the non-synonymous mutations which most likely have wide range of functional influence on viral proteins depending on the magnitude of differences in properties between the original and substituted amino acid. Although we overlooked the synonymous mutations which thought to have no phenotypic consequence on a protein, synonymous nucleotide substitution could affect mRNA folding, mRNA stability, miRNA binding and translation efficiency [39] [40] [41] . Both synonymous and non-synonymous mutations have significant effects on the adaptation, virulence, and evolution of RNA viruses. Based on non-synonymous mutational analysis, here we revealed the emergence of a novel SARS-CoV-2 lineage B.1.1.526 harbouring 11 coexisting mutations in seven different genes including D614G, P681H and V1230L in the S glycoprotein. Though the role of D614G in increased infectivity and transmissibility is well known, the functional relevance of P681H/R (previously observed in Alpha variant and Delta variant) and V1230L (first detected in this study) is yet to be determined. P681 is located adjacent to the polybasic furin cleavage site 681P-R-R-A-R-S686 where furin mediated proteolytic cleavage is expected to occur between arginine (R685) and serine (S686). This furin cleavage site is positioned at the junction between S1 domain, essential for virus binding to ACE2 receptor, and S2 domain, necessary for the fusion between virus and the cell membrane. The furin mediated cleavage at the junction of S1/S2 is essential for virus entry into the host cells [42] [43] [44] . Therefore, any mutation at this site could influence S1/S2 cleavage by furin-like proteases and hence the infection properties of the virus. V1230L mutation, not observed previously in other country, is located at the transmembrane (TM) domain of S2 subunit of S glycoprotein. This transmembrane domain anchors S glycoprotein to the virus envelope. The replacement of valine with more hydrophobic amino acid leucine might tighten the association of S glycoprotein to the viral envelope and also increase S glycoprotein incorporation into the viral envelope. Resultant high density of S glycoprotein to the viral envelope might increase the infectivity of the virus. However, further studies are required to reveal the functional relevance of this mutation. Interestingly, among 129 SARS-CoV-2 strains that encompass the novel lineage B.1.1.526, 27 strains harbour E484K mutation, which described to have role in immune evasion. Therefore, the novel lineage B.1.1.526 having D614G, P681H, V1230L and E484K mutations in the S glycoprotein is expected to have increased infectivity, high transmissibility, and immune evasion properties. Surveillance of this novel lineage is very essential to monitor the emergence of new mutations as well as to track their spread in the immediate future. 

Variant analysis of SARS-CoV-2 genomes

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cell

SARS-CoV-2 variants, spike mutations and immune escape

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus Cell

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity Cell

The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

Preliminary genomic characterisation of an emergent SARSCoV-2 lineage in the UK defined by a novel set of spike mutations

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings Virological

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Emergence of a novel SARS-CoV-2 variant in Southern California

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies bioRxiv

Triple Mutant Bengal Strain (B. 1.618) of Coronavirus and the Worst COVID Outbreak in India

Global initiative on sharing all influenza data-from vision to reality

Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations

MEGA6: molecular evolutionary genetics analysis version 6.0

MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform

Ultrafast Sample placement on Existing tRees (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic

Temporal Dominance of B. 1.1. 7 over B. 1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation

Spike mutation D614G alters SARS-CoV-2 fitness

The geographic map of West Bengal state of India, showing 9 different districts (marked with yellow colour) where the novel lineage was found. (D) The geographic map of USA, highlighting 2 different states (marked with sky blue) where B.1.1.526 was found to spread